This page shows the latest lebrikizumab news and features for those working in and with pharma, biotech and healthcare.
These studies are part of the clinical development programme for lebrikizumab in AD, assessing over 2, 000 patients. ... Patients involved in the two trials who were treated with lebrikizumab for a year continued to have relief from itching.
a 75% reduction in disease severity at 16 weeks when receiving lebrikizumab monotherapy in the programme. ... The safety profile of the 16-week period was consistent with prior lebrikizumab studies in atopic dermatitis.
The Dermira deal saw Lilly gain both a marketed drug – medicated cloth Qbrexza (glycopyrronium) for uncontrolled excessive underarm sweating – as well as pipeline candidate lebrikizumab for atopic dermatitis, which is currently
The pharma giant is also set to gain an additional phase 3 candidate from the deal – lebrikizumab, a monoclonal antibody designed to bind to IL-13 that is being evaluated for ... Roche had been developing lebrikizumab as a potential treatment for
The option deal comes amid an expansionist phase for Almirall, which exercised an option to buy Dermira’s anti-IL-13 antibody lebrikizumab – heading for phase 3 testing in atopic dermatitis
There are a number of drugs coming through the collective industry pipeline as well, including IL-13 inhibitors from Dermira (lebrikizumab) and Leo Pharma (tralokinumab) and oral JAK inhibitors such as
More from news
Approximately 4 fully matching, plus 14 partially matching documents found.
This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...